Differentiating treatment episodes from gaps in eyes with diabetic macular oedema

Macular Diseases

Biomarkers of risk of switching to dexamethasone implant for the treatment of diabetic macular oedema in real clinical practice: a multicentric study

Br J Ophthalmol

Ruiz-Medrano J, Udaondo Mirete P, Fernández-Jiménez M, Asencio-Duran M, Fernández-Vigo JI, Medina-Baena M, Flores-Moreno I, Pareja-Esteban J, Touhami S, Giocanti-Aurégan A, Cicinelli MV, Loewenstein A, Ruiz-Moreno JM

doi: 10.1136/bjo-2024-325665

Macular DiseasesRetinal Diseases

Artificial intelligence-based fluid quantification predicts clinical outcomes in diabetic macular oedema eyes treated with intravitreal dexamethasone implants: DIADEMA project

Br J Ophthalmol

Franquesa-Garcia F, Romero-Nuñez B, Martin-Pinardel R, De Zanet S, González-López JJ, Escobar-Barranco JJ, Ruiz-Del-Tiempo MP, Boixadera A, Fonollosa A, Gómez-Benlloch A, Velazquez-Villoria D, Fernández-Vigo JI, Garay-Aramburu G, Parrado-Carrillo A, Castillon L, Gómez Sánchez S, Lavid FJ, Arruabarrena C, Figueras-Roca M, Bernal-Morales C, Ciller C, Zarranz-Ventura J, DIADEMA investigators

doi: 10.1136/bjo-2025-328172

Macular Diseases

Cost-minimisation analysis of anti-VEGF therapies in neovascular age-related macular degeneration and diabetic macular oedema in Switzerland

J Med Econ

Ambresin A, Quist SW, Boer M, Maamari S, Barthelmes D

doi: 10.1080/13696998.2025.2536420

Macular Diseases

First-year real-world outcomes of faricimab in clinically significant diabetic macular oedema: a Swiss retina research network report

BMJ Open Ophthalmol

Saad A, Plasencia C, Garweg J, Pfister IB, Munk MR, Eandi CM, Zweifel SA, Grimaldi G, Bartolomeo N, Stillenmunkes R, Schild C, Cattaneo J, Gabathuler F, Menghini M, Ambersin A, Froehlich J, Artemiev D, Weinberger A, Mohamed H, Somfai GM, Hatz K

doi: 10.1136/bmjophth-2025-002467

Macular DiseasesRetinal Diseases

Visual outcomes and anatomical biomarkers of Faricimab for diabetic macular edema in the J-CREST real-world comparison of naïve and treated eyes

Sci Rep

Murao F, Yanai R, Kusuhara S, Abe Y, Shimura M, Ohara H, Terasaki H, Sugimoto M, Matsubara H, Hirano Y, Kinoshita T, Tsujinaka H, Seki K, Iwase T, Mitamura Y, J-CREST

doi: 10.1038/s41598-025-20300-6

Macular DiseasesSurgery and InterventionCataracts

Effect of combined mature cataract surgery and intravitreal ranibizumab injection in eyes with pre-existing diabetic macular edema

BMC Ophthalmol

Shen Y, Zhu X, Li AQ, Ji M, Guan HJ

doi: 10.1186/s12886-025-04264-9

Macular Diseases

Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report

Ophthalmol Sci

Spindler J, Artemiev D, Pfister IB, Schild C, Tillmann A, Heck K, Gabathuler F, Ruscitti L, Spitznagel T, Kitsos-Kalyvianakis K, Munk MR, Hatz K, Zweifel SA, Grimaldi G, Somfai GM, Ambresin A, Weinberger A, Eandi CM, Feltgen N, Kitay A, Ebneter A, Garweg JG

doi: 10.1016/j.xops.2026.101087

Macular Diseases

Eyes Achieving Absence of Diabetic Macular Edema and Very Good Vision: A Post Hoc Analysis of DRCR Network Protocol AC

Ophthalmol Retina

Ni R, Momenaei B, Mahmoudzadeh R, Salabati M, Lee HJ, Fineman MS, Yonekawa Y, Vander JF, Hsu J

doi: 10.1016/j.oret.2026.02.009

Macular Diseases

Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial

JAMA Ophthalmol

Khanani AM, Campochiaro PA, Graff JM, Marcus DM, Miller D, Mittra RA, Regillo C, Sheth VS, Bobbala A, Gune S, Lin S, Quezada-Ruiz C, Malhotra V

doi: 10.1001/jamaophthalmol.2025.0006

Related content

Biomarkers of risk of switching to dexamethasone implant for the treatment of diabetic macular oedema in real clinical practice: a multicentric study

Artificial intelligence-based fluid quantification predicts clinical outcomes in diabetic macular oedema eyes treated with intravitreal dexamethasone implants: DIADEMA project

Cost-minimisation analysis of anti-VEGF therapies in neovascular age-related macular degeneration and diabetic macular oedema in Switzerland

First-year real-world outcomes of faricimab in clinically significant diabetic macular oedema: a Swiss retina research network report

Visual outcomes and anatomical biomarkers of Faricimab for diabetic macular edema in the J-CREST real-world comparison of naïve and treated eyes

Effect of combined mature cataract surgery and intravitreal ranibizumab injection in eyes with pre-existing diabetic macular edema

Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report

Eyes Achieving Absence of Diabetic Macular Edema and Very Good Vision: A Post Hoc Analysis of DRCR Network Protocol AC

Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial